[In vitro activity of rosoxacin (Win 35 213) against Neisseria gonorrhoeae (author's transl)].
1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinoline carbonic acid (rosoxacin, Win 35 213) is a new broad-spectrum pyridyl quinoline derivative. Its activity in vitro against 247 beta-lactamase-negative and 9 beta-lactamase-positive strains of Neisseria gonorrhoeae was compared with those of penicillin, ampicillin, cefaclor, spectinomycin and tetracycline, using the microtiter-dilution technique. Rosoxacin proved to be approximately equal in activity to penicillin against penicillin-sensitive isolates of N. gonorrhoeae. Against beta-lactamase-producing isolates rosoxacin was the most active compound tested: all strains were inhibited by 0.06 mg/l.
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D011804:Quinolines / Q000494:pharmacology*; D015363:Quinolones
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin
In-vitro-Aktivität von Rosoxacin (Win 35 213) gegen Neisseria gonorrhoeae.